Literature DB >> 11222392

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.

S Li1, S Gillessen, M H Tomasson, G Dranoff, D G Gilliland, R A Van Etten.   

Abstract

Primitive hematopoietic progenitors from some patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) express aberrant transcripts for interleukin 3 (IL-3) and granulocyte colony-stimulating factor (G-CSF), and exhibit autonomous proliferation in serum-free cultures that is inhibited by anti-IL-3 and anti-IL-3 receptor antibodies. Expression of the product of the Ph chromosome, the BCR/ABL oncogene, in mice by retroviral bone marrow transduction and transplantation induces CML-like leukemia, and some leukemic mice have increased circulating IL-3, and perhaps granulocyte-macrophage colony-stimulating factor (GM-CSF). These observations raise the possibility of autocrine or paracrine cytokine production in the pathogenesis of human CML. Mice with homozygous inactivation of the Il-3 gene, the Gm-csf gene, or both, were used to test the requirement for these cytokines for induction of CML-like disease by BCR/ABL. Neither IL-3 nor GM-CSF was required in donor, recipient, or both for induction of CML-like leukemia by p210 BCR/ABL. Use of novel mice deficient in both IL-3 and GM-CSF demonstrated that the lack of effect on leukemogenesis was not due to redundancy between these hematopoietic growth factors. Analysis of cytokine levels in leukemic mice where either donor or recipient was Il-3(-/-) indicated that the increased IL-3 originated from the recipient, suggestive of a host reaction to the disease. These results demonstrate that IL-3 and GM-CSF are not required for BCR/ABL-induced CML-like leukemia in mice and suggest that autocrine production of IL-3 does not play a role in established chronic phase CML in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222392     DOI: 10.1182/blood.v97.5.1442

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

2.  Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Jami McLaughlin; Kenneth Dorshkind
Journal:  Blood       Date:  2007-06-06       Impact factor: 22.113

3.  The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Andrew W Lee; Hiroko Saito Akei; Eric B Brandt; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

4.  Mouse models as tools to understand and study BCR-ABL1 diseases.

Authors:  Steffen Koschmieder; Mirle Schemionek
Journal:  Am J Blood Res       Date:  2011-06-07

5.  Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

Authors:  Suzanne Schubbert; Kenneth Lieuw; Sara L Rowe; Connie M Lee; Xiaxin Li; Mignon L Loh; D Wade Clapp; Kevin M Shannon
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

Review 6.  Models of chronic myeloid leukemia.

Authors:  R A Van Etten
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

7.  Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.

Authors:  Daniela S Krause; Katherine Lazarides; Juliana B Lewis; Ulrich H von Andrian; Richard A Van Etten
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

8.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 9.  Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

Authors:  Michael W N Deininger
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-07       Impact factor: 4.553

10.  IL-3 and oncogenic Abl regulate the myeloblast transcriptome by altering mRNA stability.

Authors:  Jason Ernst; Louis Ghanem; Ziv Bar-Joseph; Michael McNamara; Jason Brown; Richard A Steinman
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.